Treatment of advanced non-small-cell lung cancer in the elderly: Results of an International Expert Panel

Journal of Clinical Oncology

Volumn 23, Issue 13, 2005, Pages 3125-3137

  Gridelli, Cesare ^a   Aapro, Matti ^b   Ardizzoni, Andrea ^b   Balducci, Lodovico ^b   De Marinis, Filippo ^b   Kelly, Karen ^b   Le Chevalier, Thierry ^b   Manegold, Christian ^b   Perrone, Francesco ^b   Rosell, Rafael ^b   Shepherd, Frances ^b   De Petris, Luigi ^b   Di Maio, Massimo ^b   Langer, Corey ^b  

^a S G MOSCATI HOSPITAL   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ERLOTINIB; ETOPOSIDE; GEFITINIB; GEMCITABINE; NAVELBINE; PACLITAXEL; PREDNISONE; PROSTAGLANDIN SYNTHASE INHIBITOR; PROTEASOME INHIBITOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINBLASTINE; VINCRISTINE; ANTINEOPLASTIC AGENT;

ASTHENIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL PRACTICE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG WITHDRAWAL; EXTRAVASATION; FATIGUE; FEBRILE NEUTROPENIA; GERIATRIC CARE; GERIATRIC PATIENT; HAIR LOSS; HUMAN; INFECTION; LEUKOPENIA; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MALAISE; META ANALYSIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; OTOTOXICITY; PATIENT SELECTION; PERIPHERAL NEUROPATHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; PSYCHOPATHY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RASH; REVIEW; SENSORY NEUROPATHY; SIDE EFFECT; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT CONTRAINDICATION; TREATMENT FAILURE; UNSPECIFIED SIDE EFFECT; VOMITING; WEIGHT REDUCTION; AGE; AGED; LUNG TUMOR; PATHOLOGY; RISK FACTOR;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; PATIENT SELECTION; PROGNOSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS;

EID: 21144436938     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.00.224     Document Type: Review

References (113)

1. Parkin DM: Global cancer statistics in the year 2000. Lancet Oncol 2:533-543, 2001
2. Ries LAG, Eisner MP, Kosary CL, et al: SEER Cancer Statistics Review 1975-2000. Bethesda, MD, National Cancer Institute, 2003. http://seer.cancer. gov/csr/1975_2000
3. Gridelli C, Perrone F, Monfardini S: Lung cancer in the elderly. Eur J Cancer 33:2313-2314, 1997
4. Havlik RJ, Yancik R, Long S, et al: The National Cancer Institute on Aging and the National Cancer Institute SEER: Collaborative study on comorbidity and early diagnosis of cancer in the elderly. Cancer 74:2101-2106, 1994 (suppl 7)
5. Wingo PA, Cardinez CJ, Landis SH, et al: Long term trends in cancer mortality in the United States. Cancer 97:3133-3275, 2003 (suppl 12)
6. Repetto L, Balducci L: A case for geriatric oncology. Lancet Oncol 3:289-297, 2002
7. Repetto L, Venturino A, Fratino L, et al: Geriatric oncology: A clinical approach to the older patient with cancer. Eur J Cancer 39:870-880, 2003
8. B. Fentiman IS, Tirelli U, Monfardini S, et al: Cancer in the elderly: Why so badly treated? Lancet 335:1020-1022, 1990
9. Gridelli C, Perrone F, Gallo C, et al: Chemotherapy for elderly patients with advanced non-small-cell lung cancer: The Multicenter Italian Lung cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 95:362-372, 2003
10. Di Maio M, Perrone F, Gallo C, et al. Supportive care in patients with advanced non-small-cell lung cancer. Br J Cancer 89:1013-1021, 2003
11. Borges M, Sculier JP, Paesmans M, et al: Prognostic factors for response to chemotherapy containing platinum derivatives in patients with unresectable non-small cell lung cancer. Lung Cancer 16:21-33, 1996
12. Monfardini S, Sorio R, Boes GH, et al: Entry and evaluation of elderly patients in European Organization for Research and Treatment of Cancer (EORTC) new-drug-development studies. Cancer 76:333-338, 1995
13. Hutchins LF, Unger JM, Crowley JJ, et al: Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 341:2061-2067, 1999
14. Lewis JH, Kilgore ML, Goldman DP, et al: Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol 21:1383-1389, 2003
15. Talarico L, Chen G, Pazdur R: Elderly patients in trials for cancer drug registration: A 7-year experience by the Food and Drug Administration (FDA). Proc Am Soc Clin Oncol 22:728, 2003 (abstr 2928)
16. Perrone F, Gallo C, Gridelli C: Re: Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: Implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst 94:1029-1030, 2002
17. Albain KS, Crowley JJ, LeBlanc M, et al: Survival determinants in extensive-stage non-small cell lung cancer: The Southwest Oncology Group experience. J Clin Oncol 9:1618-1626, 1991
18. Finkelstein DM, Ettinger DS, Ruckdeschel JC: Long-term survivors in metastatic non-small cell lung cancer: An Eastern Cooperative Oncology Group Study. J Clin Oncol 4:702-709, 1986
19. Stanley KE: Prognostic factors for survival in patients with inoperable lung cancer. J Natl Cancer Inst 65:25-32, 1980
20. Pereira JR, Martins SJ, Andrade LM, et al: Age and treatment of lung cancer in Brazil. Proc Am Soc Clin Oncol 19:548a, 2000 (abstr 2161)
21. Smith TJ, Penberthy L, Desch CE, et al: Differences in initial treatment patterns and outcomes of lung cancer in the elderly. Lung Cancer 13:235-252, 1995
22. Brown JS, Eraut D, Trask C, et al: Age and the treatment of lung cancer. Thorax 51:564-568, 1996
23. Earle CC, Neumann PJ, Gelber RD, et al: Impact of referral patterns on the use of chemotherapy for lung cancer. J Clin Oncol 20:1786-1792, 2002
24. Earle CC, Venditti LN, Neumann PJ, et al: Who gets chemotherapy for metastatic lung cancer? Chest 117:1239-1246, 2000
25. Non-small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311:899-909, 1995
26. Earle CC, Tsai JS, Gelber RD, et al: Effectiveness of chemotherapy for advanced lung cancer in the elderly: Instrumental variable and propensity analysis. J Clin Oncol 19:1064-1070, 2001
27. Elderly Lung Cancer Vinorelbine Italian Study (ELVIS) Group: Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 91:66-72, 1999
28. Extermann M, Albrand G, Chen H, et al: Are older French patients as willing as older American patients to undertake chemotherapy? J Clin Oncol 21:3214-3219, 2003
29. Silvestri G, Pritchard R, Welch HG: Preferences for chemotherapy in patients with advanced non-small-cell lung cancer: Descriptive study based on scripted interviews. BMJ 317:771-775, 1998
30. Balducci L: Geriatric oncology: Challenges for the new century. Eur J Cancer 36:1741-1754, 2000
31. Extermann M, Aapro M: Assessment of the older cancer patient. Hematol Oncol Clin North Am 14:63-77, 2000
32. Balducci L, Cohen HJ, Engstrom PF, et al: Senior adult oncology. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology, Version 1, 2004, National Comprehensive Cancer Center 2004. http://www.nccn.org/ professionals/physicians_gls/PDF/senior.pdf
33. Repetto L, Fratino L, Audisio RA, et al: Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: An Italian Group for Geriatric Oncology Study. J Clin Oncol 20:494-502, 2002
34. Fried LP, Tangen CM, Walston J, et al: Frailty in older adults: Evidence for a phenotype. J Gerontol A Biol Sci Med Sci 56:M146-M156, 2001
35. Saliba D, Elliott M, Rubenstein LZ, et al: The Vulnerable Elders Survey: A tool for identifying vulnerable older people in the community. J Am Geriatr Soc 49:1691-1699, 2001
36. Monfardini S, Ferrucci L, Fratino L, et al: Validation of a multidimensional evaluation scale for use in elderly cancer patients. Cancer 77:395-401, 1996
37. Perrone F, Gridelli C, Cigolari S, et al: Baseline assessment of quality of life (QoL) is a strong prognostic factor for survival of elderly patients with advanced non-small cell lung cancer (NSCLC): A secondary analysis of the MILES study. Proc Am Soc Clin Oncol 21:337a, 2002 (abstr 1346)
38. Ganz PA, Lee JJ, Siau J: Quality of life assessment: An independent prognostic variable for survival in lung cancer. Cancer 67:3131-3135, 1991
39. Colleoni M, Galon F, Nelli P, et al: Weekly vinorelbine in elderly patients with non-small-cell lung cancer. Tumori 80:448-452, 1994
40. Veronesi A, Crivellari D, Magri MD, et al: Vinorelbine treatment of advanced non-small cell lung cancer with special emphasis on elderly patients. Eur J Cancer 32A:1809-1811, 1996
41. Tononi A, Panzini I, Oliverio G, et al: Vinorelbine chemotherapy in non small cell lung cancer: Experience in elderly patients. J Chemother 9:304-308, 1997
42. Gridelli C, Perrone F, Gallo C, et al: Vinorelbine is well tolerated and active in the treatment of elderly patients with advanced non-small-cell lung cancer: A two-stage phase II study. Eur J Cancer 33:392-397, 1997
43. Buccheri G, Ferrigno D: Vinorelbine in elderly patients with inoperable nonsmall cell lung carcinoma. Cancer 88:2677-2685, 2000
44. Gridelli C, Manegold C, Mali P, et al: Oral vinorelbine given as monotherapy to advanced, elderly NSCLC patients: A multicentre phase II trial. Eur J Cancer 40:2424-2431, 2004
45. Kanard A, Jatoi A, Castillo R, et al: Oral vinorelbine for the treatment of metastatic non-small cell lung cancer in elderly patients: A phase II trial of efficacy and toxicity. Lung Cancer 43:345-353, 2004
46. Ricci S, Antonuzzo A, Galli L, et al: Gemcitabine monotherapy in elderly patients with advanced non-small cell lung cancer: A multicentre phase II study. Lung Cancer 27:75-80, 2000
47. Altavilla G, Adamo V, Buemi B, et al: Gemcitabine as single agent in the treatment of elderly patients with advanced non small cell lung cancer. Anticancer Res 20:3675-3678, 2000
48. Martoni A, Di Fabio F, Guaraldi M, et al: Prospective phase II study of single-agent gemcitabine in untreated elderly patients with stage IIIB/IV non-small-cell lung cancer. Am J Clin Oncol 24:614-617, 2001
49. Gridelli C, Cigolari S, Gallo C, et al: Activity and toxicity of gemcitabine and gemcitabine + vinorelbine in advanced non-small-cell lung cancer elderly patients: Phase II data from the Multicenter Italian Lung Cancer in the Elderly Study (MILES) randomized trial. Lung Cancer 31:277-284, 2001
50. Bianco V, Rozzi A, Tonini G, et al: Gemcitabine as single agent chemotherapy in elderly patients with stages III-IV non small cell lung cancer (NSCLC): A phase II study. Anticancer Res 22:3053-3056, 2002
51. Fidias P, Supko JG, Martins R, et al: A phase II study of weekly paclitaxel in elderly patients with advanced non-small cell lung cancer. Clin Cancer Res 7:3942-3949, 2001
52. Garbo L, Marsland T, Garfield D, et al: A phase II study of weekly paclitaxel (Taxol) in stage IIIB, IV, or relapsed after local therapy, non-small cell lung cancer (NSCLC) patients with a performance status of 2 and/or ≥70 years (yrs) of age, with (Paraplatin) administered at disease progression. Proc Am Soc Clin Oncol 20:267b, 2001 (abstr 2821)
53. West W, Birch R, Sysel I, et al: A phase II trial of weekly paclitaxel in elderly patients or those with decreased performance status with advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 20:258b, 2001 (abstr 2782)
54. Hainsworth JD, Burris HA, Litchy S, et al: Weekly docetaxel in the treatment of elderly patients with advanced nonsmall cell lung carcinoma. Cancer 89:328-333, 2000
55. Lilenbaum R, Rubin M, Samuel J, et al: A phase II randomized trial of docetaxel weekly or every 3 weeks in elderly and/or poor performance status patients with advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 23:627, 2004 (abstr 7057)
56. Frasci G, Lorusso V, Panza N, et al: Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol 18:2529-2536, 2000
57. Shepherd FA, Abratt RP, Anderson H, et al: Gemcitabine in the treatment of elderly patients with advanced non-small cell lung cancer. Semin Oncol 24:S750-S755, 1997 (suppl 7)
58. Martin C, Ardizzoni A, Rosso R: Gemcitabine: Safety profile and efficacy in non-small cell lung cancer unaffected by age. Aging (Milano) 9:297-303, 1997
59. Furuse K: Gemcitabine in the treatment of non-small cell lung cancer for elderly patients. Gan To Kagaku Ryoho 26:890-897, 1999
60. Nakamura Y, Sekine I, Furuse K, et al: Retrospective comparison of toxicity and efficacy in phase II trials of 3-h infusions of paclitaxel for patients aged 70 years of age or older and patients under 70 years of age. Cancer Chemother Pharmacol 46:114-118, 2000
61. Inoue A, Kunitoh H, Mori K, et al: Phase I trial of weekly docetaxel in elderly patients with non-small cell lung cancer. Lung Cancer 38:205-209, 2002
62. Hesketh PJ, Chansky K, Lau DH, et al: Sequential vinorelbine and docetaxel in advanced non-small cell lung cancer patients age > 70, or with performance status 2: A SWOG phase II trial (S0027). Proc Am Soc Clin Oncol 23:627, 2004 (abstr 7056)
63. Kimura H, Kasahara K, Shibata K, et al: A phase II trial of biweekly administration of vinorelbine and gemcitabine in elderly patients with advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 23:695, 2004 (abstr 7331)
64. Beretta GD, Michetti G, Belometti MO, et al: Gemcitabine plus vinorelbine in elderly or unfit patients with non-small cell lung cancer. Br J Cancer 83:573-576, 2000
65. Chen YM, Perng RP, Chen MC, et al: A phase II trial of vinorelbine plus gemcitabine in previously untreated inoperable (stage IIIb/IV) non-small-cell lung cancer patients aged 80 or older. Lung Cancer 40:221-226, 2003
66. Feliu J, Gómez LL, Madronal C, et al: Gemcitabine plus vinorelbine in nonsmall cell lung carcinoma patients age 70 years or older or patients who cannot receive cisplatin. Cancer 86:1463-1469, 1999
67. Le Chevalier T, Brisgand D, Douillard JY, et al: Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small cell lung cancer: Results of a European Multicenter Trial including 612 patients. J Clin Oncol 12:360-367, 1994
68. Ranson M, Davidson N, Nicolson M, et al: Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 92:1074-1080, 2000
69. Comella P, Frasci G, Carnicelli P, et al: Gemcitabine with either paclitaxel or vinorelbine vs paclitaxel or gemcitabine alone for elderly or unfit advanced non-small-cell lung cancer patients. Br J Cancer 91:489-497, 2004
70. Hainsworth JD, Erland JB, Barton JH, et al: Combination treatment with weekly docetaxel and gemcitabine for advanced non-small cell lung cancer in elderly patients and patients with poor performance status: Results of a Minnie Pearl Cancer Research Network phase II trial. Clin Lung Cancer 5:33-38, 2003
71. American Society of Clinical Oncology: Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer: Adopted on May 16, 1997 by the American Society of Clinical Oncology. J Clin Oncol 15:2996-3018, 1997
72. Pfister DG, Johnson DH, Azzoli CG, et al: American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: Update 2003. J Clin Oncol 22:330-353, 2004
73. ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of non-small-cell lung cancer (NSCLC). Ann Oncol 12:1049-1050, 2001
74. Oshita F, Kurata T, Kasai, et al: Prospective evaluation of the feasibility of cisplatin-based chemotherapy for elderly lung cancer patients with normal organ functions. Jpn J Cancer Res 86:1198-1202, 1995
75. Rinaldi M, De Marinis F, Ardizzoni A, et al: Correlation between age and prognosis in patients with advanced non small cell lung cancer treated with cisplatin containing chemotherapy: A retrospective multicentre study. Ann Oncol 5:58, 1994 (suppl 8)
76. Kubota K, Hosomura K, Kakinuma R, et al: Cisplatin nephrotoxicity in elderly patients with lung cancer. Proc Am Soc Clin Oncol 17:491a, 1998 (abstr 1890)
77. Lichtman SM, Buchholtz M, Marino J, et al: Use of cisplatin for elderly patients. Age Ageing 21:202-204, 1992
78. Thyss A, Saudes L, Otto J, et al: Renal tolerance of cisplatin in patients more than 80 years old. J Clin Oncol 12:2121-2125, 1994
79. Cubillo A, Cornide M, Lopez JL, et al: Renal tolerance to cisplatin in patients 70 years and older. Am J Clin Oncol 24:192-197, 2001
80. Nguyen B, Sandler A, Denham C: The safety and efficacy of gemcitabine plus cisplatin in the elderly chemo-naïve NSCLC patients (age a 70 years) as compared to those with age < 70 years. Proc Am Soc Clin Oncol 18:471a, 1999 (abstr 1818)
81. Kelly K, Giarritta S, Akerley W, et al: Should older patient (pts) receive combination chemotherapy for advanced stage non-small cell lung cancer (NSCLC)? An analysis of Southwest Oncology Trials 9509 and 9308. Proc Am Soc Clin Oncol 20:329a, 2001 (abstr 1313)
82. Langer CJ, Manola J, Bernado P, et al: Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: Implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst 94:173-181, 2002
83. Lilenbaum RC, Herndon J, List M, et al: Single-agent (SA) vs combination chemotherapy (CC) in advanced non-small cell lung cancer (NSCLC): a CALGB randomized trial of efficacy, quality of life (QOL), and cost-effectiveness. Proc Am Soc Oncol 21:1a, 2002 (abstr 2)
84. Rocha Lima CMS, Herndon JE, Kosty M, et al: Therapy choices among older patients with lung carcinoma. Cancer 94:181-187, 2002
85. Langer CJ, Vangel J, Schiller DP, et al: Age-specific subanalysis of ECOG 1594: fit elderly patients (70-80 yrs) with NSCLC do as well as younger patients (< 70). Proc Am Soc Clin Oncol 22:639, 2003 (abstr 2571)
86. Fossella FV, Belani CP: Phase II study (TAX 326) of docetaxel-cisplatin (DC) and docetaxel-carboplatin (DCb) versus vinorelbine-cisplatin (VC) for the first-line treatment of advanced/metastatic non-small-cell-lung cancer (NSCLC): analysis in elderly patients. Proc Am Soc Clin Oncol 22:629, 2003 (abstr 2528)
87. Hensing TA, Peterman AH, Schell MJ, et al: The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, stage IIIB or IV nonsmall cell lung carcinoma treated with carboplatin and paclitaxel. Cancer 98:779-788, 2003
88. Lippe P, Silva RR, Giuliodori L, et al: Advanced non-small cell lung cancer in the elderly: Effective and well tolerated weekly gemcitabine and cisplatin regimen-A pilot study. Minerva Med 91:53-57, 2000
89. Berardi R, Porfiri E, Scartozzi M, et al: Elderly patients with advanced non-small cell lung cancer: A phase II study with weekly cisplatin and gemcitabine. Oncology 65:198-203, 2003
90. Feliu J, Martin G, Madronal C, et al: Combination of low-dose cisplatin and gemcitabine for treatment of elderly patients with advanced non small cell lung cancer. Cancer Chemother Pharmacol 52:247-252, 2003
91. Martins SJ, Pereira JR, Ikari FK, et al: Chemotherapy with cisplatin and vinorelbine for elderly non-small cell lung cancer patients. Proc Am Soc Clin Oncol 18:468a, 1999 (abstr 1804)
92. Ohe Y, Niho S, Kakinuma R, et al: A phase II study of cisplatin and docetaxel administered as three consecutive weekly infusions for advanced non-small-cell lung cancer in elderly patients. Ann Oncol 15:45-50, 2004
93. Maestu IC, Gómez-Aldaraví L, Torregrossa MD, et al: Gemcitabine and low dose carboplatin in the treatment of elderly patients with advanced non-small cell lung cancer. Lung Cancer 42:345-354, 2003
94. Okamoto I, Moriyama E, Kishi H, et al: Multicenter phase II study of the combination of carboplatin and paclitaxel as first line treatment in elderly patients with advanced non small cell lung cancer. Proc Am Soc Clin Oncol 23:672, 2004 (abstr 7239)
95. Choi IS, Kim BS, Park SR, et al: Efficacy of modified regimen with attenuated doses of paclitaxel plus carboplatin combination chemotherapy in elderly and/or weak patients with advanced non small cell lung cancer. Lung Cancer 39:99-101, 2003
96. Molinier O, Milleron B, Breton JL, et al: Multicenter phase II trial of carboplatin and weekly paclitaxel as first-line treatment in elderly patients with non small cell lung cancer: Preliminary results. Proc Am Soc Clin Oncol 22:693, 2003 (abstr 2786)
97. Cohen MH, Williams GA, Sridhara R, et al: FDA approval summary: Gefitinib (ZD1839) (Iressa) tablets. Oncologist 8:303-306, 2003
98. Copin M, Kommareddy A, Behnken D, et al: Gefitinib in elderly patients with non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 22:758, 2003 (abstr 3048)
99. Gridelli C, Maione P, Castaldo V, et al: Gefitinib in elderly and unfit patients affected by advanced non-small cell lung cancer. Br J Cancer 89:1827-1829, 2003
100. Soto Parra H, Cavina R, Zucali P, et al: Gefitinib in elderly patients with progressive, pretreated, non small cell lung cancer: Results from the Istituto Clinico Humanitas. Br J Cancer 89:S25-S35, 2003 (suppl 2)
101. Stahel R, Rossi A, Petruzelka L, et al: Lessons from the "Iressa" Expanded Access Programme: Gefitinib in special non-small-cell lung cancer patient populations. Br J Cancer 89:S19-S23, 2003 (suppl 2)
102. Cappuzzo F, Bartolini S, Ceresoli GL, et al: Efficacy and tolerability of gefitinib in pretreated elderly patients with advanced non-small-cell lung cancer (NSCLC). Br J Cancer 90:82-86, 2004
103. Scagliotti G, Rossi A, Novello S, et al: Gefitinib (ZD1839) combined with gemcitabine or vinorelbine as single-agent in elderly patients with advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 23:633, 2004 (abstr 7081)
104. Giaccone G, Herbst RS, Manegold C, et al: Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT 1. J Clin Oncol 22:777-784, 2004
105. Herbst RS, Giaccone G, Schiller JH, et al: Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT 2. J Clin Oncol 22:785-794, 2004
106. Shepherd FA, Pereira J, Ciuleanu TE, et al: A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy: A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial. Proc Am Soc Clin Oncol 22:6225 (abstr 7022)
107. Johnson BE, Lucca J, Rabin MS, et al: A phase II trial of erlotinib in previously untreated elderly patients (> 70 years) with advanced NSCLC: Preliminary results. Ann Oncol 15:iii169, 2004 (suppl 3; abstr 639PD)
108. Maione P, Rossi A, Airoma G, et al: The role of targeted therapy in non-small cell lung cancer. Crit Rev Oncol Hematol 51:29-44, 2004
109. Repetto L, Biganzoli L, Koehne CH, et al. EORTC Cancer in the Elderly Task Force guidelines for the use of colony-stimulating factors in elderly patients with cancer. Eur J Cancer 39: 2264-2272, 2003
110. Di Maio M, Gridelli C, Gallo C, et al: Prevalence and management of pain in Italian patients with advanced non-small-cell lung cancer. Br J Cancer 90:2288-2296, 2004
111. Gridelli C, Ardizzoni A, Le Chevalier T, et al: Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: Results of an European Experts Panel. Ann Oncol 15:419-426, 2004
112. National Cancer Institute: PDQ National Cancer Institute clinical trials database. http://www.cancer.gov/clinical_trials
113. Slevin ML, Stubbs L, Plant HJ, et al: Attitudes to chemotherapy: Comparing view of patients with cancer with those of doctors, nurses and general public. BMJ 300:1458-1460, 1990